Gino K. In, MD, MPH, and Lara A. Dunn, MD, review updated long-term follow-up data on cosibelimab from the CK-301-101 study and discuss what its efficacy, durability, and tolerability mean for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
Gino K. In, MD, MPH, of the USC Norris Comprehensive Cancer Center, and Lara A. Dunn, MD, of Memorial Sloan Kettering Cancer Center, open a discussion of newly reported long-term follow-up data on cosibelimab in locally advanced cutaneous squamous cell carcinoma.
Dr. Dunn describes how she uses immune checkpoint inhibitors in locally advanced cutaneous squamous cell carcinoma, distinguishing neoadjuvant therapy from checkpoint blockade given as a replacement for curative therapy.
